#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Neurofibromatosis Propionic acidaemia Corneal neovascularisation Immune-mediated renal disorder Chronic lymphocytic leukaemia refractory Chondrosarcoma Thrombotic microangiopathy Immunoglobulin G4 related disease Cutaneous calcification Sickle cell anaemia Ocular myasthenia Anti-HLA antibody test positive Acute myeloid leukaemia recurrent Retinitis pigmentosa Myelin oligodendrocyte glycoprotein antibody-associated disease More trials…

    Learn about Rare Diseases

    Immunodeficiency congenital Waldenstrom’s macroglobulinaemia refractory – Trials in Disease Rhabdomyosarcoma recurrent Biotinidase deficiency Hereditary motor and sensory neuropathy – Diagnostics SAPHO syndrome – Trials in Disease Osteosarcoma – Trials in Disease Osteosarcoma metastatic – Treatment Waldenstrom’s macroglobulinaemia recurrent – Diagnostics Primary hyperoxaluria – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Serpina1(Human)-Aav8-1 Galunisertib Navitoclax Caspofungin SOVATELTIDE Imlifidase Antiemetics And Antinauseants L-PROLINE Dermatophagoides Farinae Cl-Ad-Msc-002 Ibrutinib Selumetinib Givinostat APROTININ Xp-Dc+Tl+Klh RO7268489 Temocillin Clarithromycin Midodrine Hydrochloride Sertindole More therapies…

    Learn about Your Condition

    Acute lymphocytic leukaemia Eye inflammation Necrotising myositis Primary hypercholesterolaemia Pancreatitis chronic Gouty arthritis Tendon rupture Alport's syndrome Renal cancer Complicated appendicitis Erythema migrans Fibrosarcoma metastatic Coronary artery occlusion Herpes simplex meningitis Hypoalbuminaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Comparison of belantamab mafodotin, bortezomib and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Belantamab Mafodotin
    • Dexamethasone Ph. Eur.
    • Bortezomib
    Belgium Czechia France Germany Greece Italy +3

  • Study on Self-Administration of Elranatamab for Patients with Multiple Myeloma at Home

    Recruiting

    2 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Elranatamab
    Denmark

  • Study of Teclistamab and Lenalidomide as Maintenance Treatment for Newly Diagnosed Multiple Myeloma Patients After Stem Cell Transplantation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Teclistamab
    • Lenalidomide
    Austria Belgium Czechia Denmark France Germany +7

  • Long-Term Follow-Up Study for Patients with Myxoid/Round Cell Liposarcoma, Multiple Myeloma, Non-Small Cell Lung Cancer, or Synovial Sarcoma Treated with Letetresgene Autoleucel

    Recruiting

    1 1 1
    Investigated Drugs:
    • Letetresgene Autoleucel
    France Italy The Netherlands Spain

  • Study on Linvoseltamab and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Have Not Yet Received Treatment

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Linvoseltamab
    • Dexamethasone
    France Spain

  • Long-term Safety Study of Ciltacabtagene Autoleucel for Patients with Multiple Myeloma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Ciltacabtagene Autoleucel
    Belgium France The Netherlands Spain
Previous Page
1 … 5 6 7 8 9 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!